Fortrea 召開的研究中心諮詢委員會會議匯集研究領導者，重點關注不斷發展的研究中心、贊助商和患者關係北卡羅來納州，達勒姆, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE)（下稱「公司」），一家全球領先的合同研究組織 (CRO)，今天宣布，上週召開了研究中心諮詢委員會的首次會議，該委員會是臨床研究試驗主持人研究中心（下稱「研究中心」）和行業領導者之間的合作，旨在透過針對技術、營運規劃和交付、商業條款和社群參與方面的變革為研究中心、患者和臨床研究贊助商（下稱「贊助商」）創造更好的臨床試驗體驗。 Fortrea 將研究中心和試驗主持人置於臨床試驗規劃的重要位置，利用他們的觀點推動變革，從而提高試驗執行速度、簡化研究啟動並提高招募效率。這些變化解決了臨床試驗中長期存在的挑戰，並將帶來更好的研究中心、患者和贊助商試驗體驗。研究中心諮詢委員會將負責就研究中心、患者、試驗營運和相關技術提出的策略和解決方案提供見解和反饋。 「在臨床開發的每個階段，研究中心和試驗主持人對本行業至關重要，傳統上他們僅在臨床試驗中就面臨難以解決的挑戰。我們歡迎他們在研究方案設計 ...

合作利用 Medidata AI 提高不同人群在臨床研究中的接入及參與北卡羅來納州，達勒姆, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq：FTRE），一家全球領先的合同研究組織 (CRO)，今天宣布與 Medidata 建立合作伙伴關係，Medidata 是 Dassault Systèmes 公司和生命科學行業臨床試驗解決方案的領先提供商，將使用 Medidata AI Intelligent Trials 來增加 Fortrea 進行的臨床試驗中多元化患者的接入。 Fortrea 使用 Medidata AI 是基於兩家公司已有的合作關係，擴大了 Fortrea 使用 Medidata Rave EDC 的範圍，這是一種用於臨床試驗站點患者和實驗室數據捕獲和管理的先進、強大且安全的 EDC 系統。Fortrea 將利用 Medidata AI Intelligent Trials 的特性，包括研究可行性和多元化數據，幫助新興和大型生物製藥公司，以及醫療設備和診斷公司，實現招募目標，反映出每種疾病或研究條件下受影響最大的人群。 「Medidata 的數 ...

Financial Data and Key Metrics Changes - The company reported revenues of $776 million in Q3 2023, representing a 1.8% increase year-over-year [40] - Adjusted EBITDA for the quarter was $70.5 million, a decrease of 33% year-over-year compared to $105.2 million in the prior year period [24] - Adjusted net income for the quarter was $21.3 million, down 73.5% from $80.3 million in the prior year period [44] - Year-to-date adjusted basic and diluted earnings per share were $1.22 and $1.21, respectively, compared to $2.48 in the prior year period [25] Business Line Data and Key Metrics Changes - Clinical Services revenues were $712 million, growing 2.1% year-on-year, driven by higher pass-through revenues [40] - Enabling Services revenues were nearly $65 million, broadly flat year-on-year, driven by growth in the Endpoint business [21] - The company achieved a book-to-bill ratio of 1.24, indicating a healthy mix of work [15] Market Data and Key Metrics Changes - The company’s backlog grew 2.2% sequentially, ending the quarter at $7.1 billion [39] - Days sales outstanding (DSO) increased to 92 days, up six days from the previous quarter [45] Company Strategy and Development Direction - The company aims to transform into a competitive independent CRO, focusing on serving biotech and selectively larger pharma [7][34] - Investments are being made in technology and geographic leadership to enhance operational efficiency and customer offerings [47][51] - The company is focused on exiting transition services agreements (TSAs) to reduce costs and improve margins [50][76] Management's Comments on Operating Environment and Future Outlook - Management noted that the demand environment remains solid, with no significant slowdown among larger pharma customers [92] - The company is optimistic about the pipeline for Q4, expecting a solid book-to-bill ratio with a healthy mix of work [134] - Management emphasized the importance of delivering results and maintaining strong customer relationships to drive future growth [80][81] Other Important Information - The effective tax rate for the quarter was 26.8%, with expectations for the full-year adjusted effective tax rate to be between 27% and 30% [23] - The company is undertaking a review of its structure to optimize its tax strategy [43] Q&A Session Summary Question: Can you walk us through the SG&A analysis and how it relates to gross margin? - Management indicated that significant margin expansion opportunities exist, particularly in IT and finance, which are interrelated with exiting TSAs [57][60] Question: How is the competitive landscape evolving post-spin? - Management noted that large wins were competitive with larger CROs, and there is a positive reception from customers regarding the company’s independence [94] Question: Can you elaborate on the demand environment and organic improvements? - Management highlighted ongoing innovation in the industry and a solid flow of RFPs from larger pharma and biotech customers [92] Question: What is the strategy regarding large pharma and biotech? - The company confirmed a nuanced strategy focusing on biotech while selectively engaging with large pharma, emphasizing quality and resource allocation [100][127] Question: What are the expectations for adjusted EBITDA in 2024? - Management refrained from providing specific guidance but indicated a cautious optimism based on new awards and backlog conversion rates [101][119]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-41704 FORTREA HOLDINGS INC. (Exact name of registrant as specified in its charter) | Delaware | 92-2796441 | | --- | --- ...

透過現場藥房的 cGMP 生產增加速度和靈活性，增加容量，提高靈活的治療能力，並增強研究志願者的體驗北卡羅來納州，杜倫, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE)（下稱「該公司」），一家領先的全球合同研究組織 (CRO)，今天宣布已完成多年努力擴展其臨床藥理學解決方案和能力，現已完全可供客戶使用。該擴展包括位於英國利茲的 100,000 平方英呎的最先進設施，以及約 20,000 平方英呎的新建或翻新空間，增加了位於德州達拉斯、佛羅里達州代托納和威斯康星州麥迪遜的臨床研究單位 (CRUs) 的容量和能力。 Fortrea 臨床藥理學總裁兼醫院行政總監 Oren Cohen 博士表示：「臨床藥理學研究的日益複雜性要求適宜的基礎設施、經驗和專業知識，以保護研究參與者的安全和至關重要的數據的完整性。」他補充說：「我們的綜合服務平台包括一流的基礎設施和經驗豐富的專業人員，他們完全致力於臨床藥理學，包括醫生、護士、臨床科學家、CRA 和藥動學家。我們所進行的投資旨在提升客戶需要準確評估早期研發階段候選品並加快有前景的候選品進入後期開發階段，最終惠及 ...

Fortrea Holdings Inc. (NASDAQ:FTRE) Q2 2023 Earnings Call Transcript August 14, 2023 8:00 AM ET Company Participants Hima Inguva - Head of IR Tom Pike - President & CEO Jill McConnell - CFO Mark Morais - COO Conference Call Participants David Windley - Jefferies Elizabeth Anderson - Evercore Casey Woodring - JPMorgan Max Smock - William Blair Sandy Draper - Guggenheim Derik De Bruin - Bank of America Operator Good morning, and thank you for standing by. Welcome to the Fortrea Second Quarter 2023 Earnings Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number 001-41704 FORTREA HOLDINGS INC. (Exact name of registrant as specified in its charter) | Delaware | 92-2796441 | | --- | --- | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 8 Moore Drive Durham, North Carolina | | | ...